Laura joined EyeBio in 2022 as the Vice President of Quality Assurance. In this role, she implements the structure for the quality management system and provides quality oversight for the operational teams developing advanced therapies for eye diseases.
Laura brings over 25 years of strategic quality compliance experience in drug development, with a focus on retinal diseases and rare diseases. Additionally, she has provided quality oversight to teams developing ATMPs for rare diseases and has successfully managed a variety of Health Authority inspections.
Laura holds an MBA, as well as an MS from Temple University and Doctorate degree from the University of Southern California, both focusing on Regulatory Science.
